The prostate cancer therapeutics market is expected to reach $23.2 billion by 2025, with a compound annual growth rate (CAGR) of 6.1% over the forecast period.
Table of Contents
Prostate Cancer Therapeutics Market – Introduction
The global prostate cancer therapeutics market is expected to grow at a fast pace during the forecast period of 2017 to 2025. In the prostate cancer therapeutics market report, the market is segmented based on therapy type and region. Prostate is a gland in the male reproductive system, and cancer that develops in that gland is known as “prostate cancer.”The exact causes of prostate cancer are unknown, but it is generally linked to hereditary causes or to an unhealthy diet and lifestyle. According to studies, eating a lot of red meat and processed meat raises your chances of getting prostate cancer, and having a family history of prostate cancer raises your chances even more.
Prostate cancer is also often linked to exposure to harmful chemicals and pathogens, among others. Prostate cancer has a relatively low mortality rate, and a combination of prostate cancer therapeutics has been found to increase the survival rate to a large extent. While prostate cancer is mostly prevalent in developed nations, the growing patient pool in emerging economies has been primarily driving the prostate cancer therapeutics market revenue and volume.
Report Overview
| Aspect | Details |
| Base year of Estimation | 2016 |
| Value Estimation Year | 2017 |
| Forecast Period | 2017 – 2025 |
| Market Segmentation | By Therapy Type, Regions |
| Regional Scope | North America, Asia Pacific, Europe, Middle East & Africa and Latin America |
| Report Coverage | Market Dynamics, Segmentation Overview and Competitive Landscape of the market |
Segmentation Overview
| Segment | Details |
| By Therapy Type | Biologic Therapy, Chemotherapy, Hormone Therapy and Others |
| By Regions | North America, Asia Pacific, Europe, Middle East & Africa and Latin America |
Major Players
| Headquarters | Corporations |
| The U.S | Pfizer, Inc., Johnson & Johnson, Amgen, Inc. |
| England | AstraZeneca Plc |
| Germany | Bayer AG |
| France | Sanofi S.A |
What Are the Driving Factors for Prostate Cancer Therapeutics Market?
- Increasing number of patients in emerging economies, developed nations
- Growing usage of hormone-refractory prostate cancer drugs
- Approval of new drugs such as Xofigo of Bayer, enzalutimide and inclusion of new curative methods
Why Buy this Prostate Cancer Therapeutics Market Report?
- The report provides in-depth analysis of market determinant factors.
- It analyzes market dynamics for each segment (such as Therapy Type, Regions).
- This report provides 8 years forecast by analyzing push and pull factors affecting the dynamics of the market.
- It provides application level cross sectional analysis for each product type.
- It provides regional level pricing trend analysis.
- This market report acts as business decision support system by analyzing key trends in each market segment.
- It provides insights regarding business strategies of leading market players.
Market Dynamics
Prostate cancer therapeutics market growth trends are primarily due to the rising patient pool globally. Studies reveal that the number of prostate cancer patients has been growing at a fast pace in emerging economies apart from the fast growth rates in developed nations. As per the World Health Organization (WHO), prostate cancer is the fourth most prevalent form of cancer and approximately 1.1 million males were diagnosed with the disease in 2012. Significant rises in prostate cancer cases were noticed in countries such as Denmark, Singapore, Slovakia, Colombia, and Costa Rica, among other countries. Such a growing number of patients has led to increasing demand for the different types of prostate cancer therapeutics, thus positively impacting the growth of the prostate cancer therapeutics market size.
The growing usage of hormone-refractory prostate cancer drugs, coupled with the approval of several new drugs and therapies, has also been driving the growth of the prostate cancer therapeutics market. Hormone-refractory prostate cancer drugs have been found to have relatively fewer adverse effects, thus having higher acceptance in patients, which in turn has been boosting the growth of the prostate cancer therapeutics market.
Lack of proper diagnosis methods and the relatively high cost of treatment are some of the factors which have been restraining the growth rate of the prostate cancer therapeutics market. Since prostate cancer is mostly asymptomatic, low diagnosis rates decrease the chances of the patients receiving the drugs at an optimum time, thus restraining the growth. However, the approval of several new prostate cancer drugs, such as Xofigo by Bayer and enzalutimide, among others, is expected to negate such restraints for the prostate cancer therapeutics market and is also expected to offer good growth opportunities.
Segmentation Overview
By Therapy Type
The global prostate cancer therapeutics market is segmented, based on therapy type, into biologic therapy, chemotherapy, hormone therapy and others. Chemotherapy has been sub segmented into systemic chemotherapy and regional chemotherapy. Hormone therapy has again been segmented into luteinizing hormone releasing hormone (LHRH) analogues, LHRH antagonists and others. Hormone therapy is the most preferred form of therapy in prostate cancer patients and hence was the leading segment of the prostate cancer therapeutics segment in 2016, by revenue.
- Biologic Therapy,
- Chemotherapy,
- Hormone Therapy and Others
By Geography
By geography, the market has been segmented into Europe, North America, Middle East & Africa (MEA),Asia Pacific and Latin America. In terms of revenue, North America accounted for the largest market share of the prostate cancer therapeutics market, followed by Europe.
- North America,
- Asia Pacific,
- Europe,
- Middle East & Africa and
- Latin America
Competitive Landscape
Majorcompanies operating in the prostate cancer therapeuticsmarket are Pfizer, Inc. (The U.S.), AstraZeneca Plc (England), Bayer AG. (Germany), Johnson & Johnson (The U.S.), Amgen, Inc. (The U.S.), and Sanofi S.A. (France) among others.
The latest news from the industry straight to your inbox.
Join 2,000+ subscribers for exclusive access to our monthly newsletter with market research data, industry news.
